次临界溶液堆生产钼-99初步研究  

作　　者：刘锋[1] 夏兆东[1] 潘翠杰[1] 

机构地区：[1]中国原子能科学研究院,北京102413

出　　处：《科学技术创新》2021年第12期50-52,共3页Scientific and Technological Innovation

基　　金：国家自然科学基金资助项目(11775310)。

摘　　要：医用同位素99mTc在心血管、肿瘤等疾病的诊断中发挥着重要的作用,随着99mTc的需求量越来越大,其母体核素99Mo的需求量也不断增加。文章介绍了美国近年来在加速器驱动的次临界铀溶液系统生产99Mo工艺的研究进展,随后利用蒙卡程序模拟计算了D-T中子管驱动的次临界铀溶液系统生产99Mo产物活度,总结了次临界下生产99Mo的优缺点,为我国未来同位素生产的工业化提供一条可行性高的技术路线。The medical isotope 99mTc plays an important role in the diagnosis of cardiovascular,tumor and other diseases.With the increasing demand of 99mTc,the demand of its parent nuclide 99Mo is also increasing.This paper introduces the research progress of the 99Mo process in the production of subcritical uranium solution system driven by accelerator in the United States in recent years.Then,the 99Mo product activity simulation was calculated with Monte Carlo code based on the subcritical uranium solution system driven by D-T neutron tube,and the advantages and disadvantages of producing 99Mo under subcritical were summarized.It provides a highly feasible technical route for the industrialization of isotope production in China in the future.

关 键 词：医用同位素 次临界装置 铀溶液 同位素生产 钼-99 

分 类 号：R81[医药卫生—放射医学]